The purpose of this research is to assess the continued safety and efficacy of the Esprit BTK system, which was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of narrowed arteries below the knee in patients with Chronic Limb-Threatening Ischemia (CLTI).

Participants may enroll in the study if this stent is used during their procedure. 

Study participation will last for three years, with follow-up visits (after the procedure) at 30 days, 90 days, 180 days, 1 year, 2 years, and 3 years.

The purpose of this study is to collect data on the use of commercially approved Boston Scientific drug-eluting devices used to treat peripheral vascular disease (PAD) to understand how these devices are being used in a routine hospital setting. We hope to potentially improve patient outcomes in the future as well as to understand how patient outcomes compare across diverse patient populations. The study data will also be used to continue monitoring the safety of these devices.

This clinical trial is designed for men and women with stage 4 squamous and non-squamous (NSCLC) who have not received prior systemic therapy for the advanced disease.
   
The purpose of this study is to evaluate the safety and tolerability of EIK1001 with pembrolizumab and chemotherapy in participants with histologically confirmed Stage 4 non-squamous or squamous NSCLC.

This study is evaluating what the safest and most tolerable dose of enfortumab vedotin that can be taken in combination with the standard dose of erdafitinib for metastatic urothelial carcinoma. This study aims to find out if this approach is better or worse than the usual approach for metastatic bladder cancer. The usual approach is defined as care most people get for metastatic bladder cancer.

This clinical trial is for adults who have a brain tumor (glioblastoma) that has gotten worse despite first treatment and for whom additional surgery and chemotherapy are being recommended to treat their tumor.
   

This clinical trial is for men and women who have been diagnosed with clonal cytopenias of uncertain significance (CCUS) that is clinically significant.

The purpose of this study is to learn whether luspatercept is successful in improving blood counts in patients with clonal cytopenias of uncertain significance (CCUS). Luspatercept is a U.S. Food and Drug Administration (FDA) -approved drug for myelodysplastic syndrome (MDS) but is not approved for CCUS.

The purpose of this study is to evaluate the safety and effectiveness of the investigational Stryker Citadel Embolization Device for use in the treatment of patients with an aneurysm in the brain. A brain (cerebral) aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain.

This device is an investigational device that has not been approved by the U.S. Food & Drug Administration (FDA) for treatment of this type of aneurysm. 

This research study is evaluating an investigational treatment called vedolizumab for moderately to severely active ulcerative colitis (UC) or Crohn's Disease (CD) in children. The purpose of this study is to find out how vedolizumab is processed by the bodies of children with moderately to severely active UC or CD, test to see whether the body makes antibodies against vedolizumab, test how safe vedolizumab is in children, and find out how vedolizumab may affect quality of life and g

This study aims to learn ways to improve the way MRI scans are done to make them more accurate and easier for patients, particularly by using a method that allows them to breathe normally during the scan. 

We also hope to learn ways to improve our understanding of kidney disease. This could lead to better diagnostic tools, more effective treatments, and a deeper insight into kidney function and failure, ultimately benefiting future patients. 

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated).